David J. Blythin

The pharmacology of SCH 50911: a novel, orally-active GABA-beta receptor antagonist.

Donald C. Bolser, David J. Blythin, Richard W. Chapman et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 77 citations

Cyclic urea derivatives as potent NK1 selective antagonists

Ho‐Jane Shue, Xiao Chen, Neng‐Yang Shih et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 46 citations

Medicinal Chemistry, Cyclic Urea Derivatives, Functional Selectivity +5

Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents

David J. Blythin, James J. Kaminski, Martin S. Domalski et al. · Journal of Medicinal Chemistry · 1986 · 43 citations · Full text

Medicinal Chemistry, Possible Isomers, Pharmaceutical Science +12

Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors

Rongze Kuang, Ho‐Jane Shue, David J. Blythin et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 33 citations · Full text

Medicinal Chemistry, Biochemistry, Oxazole-based Phosphodiesterase 4 +11

Enantioselective syntheses of carbocyclic ribavirin and its analogs: linear versus convergent approaches

Rongze Kuang, Ashit K. Ganguly, Tze-Ming Chan et al. · Tetrahedron Letters · 2000 · 30 citations

Carbocyclic Ribavirin, Engineering, Diversity-oriented Synthesis +8